Pfizer's HYMPAVZI Receives FDA Priority Review for Hemophilia Treatment

Written by Emily J. Thompson, Senior Investment Analyst

Source: Businesswire

Updated: 1h ago

0mins

PFE-1.08%

Should l Buy PFE?

Source: Businesswire

FDA Priority Review: Pfizer's HYMPAVZI (marstacimab) has received FDA Priority Review to expand its indication for patients aged 6 and older with hemophilia A or B, with a decision expected in Q2 2026, which could provide a more effective treatment option and meet the urgent market demand for new therapies.
Clinical Trial Support: The application for HYMPAVZI is supported by efficacy and safety data from the BASIS clinical trial, demonstrating its potential to reduce bleeding frequency, particularly in pediatric patients aged 6 to 11, which could transform the existing treatment landscape and enhance Pfizer's competitiveness in the hemophilia market.
Treatment Need: Hemophilia affects over 800,000 people globally, with approximately 20% of hemophilia A patients and 3% of hemophilia B patients developing inhibitors, and the introduction of HYMPAVZI will provide new treatment options for these patients, addressing the current limitations in available therapies.
Innovative Mechanism: HYMPAVZI targets tissue factor pathway inhibitor (TFPI) rather than traditional factor replacement therapies, offering a once-weekly subcutaneous injection that simplifies the treatment process, which is expected to improve patient adherence and quality of life, further solidifying Pfizer's leadership in the biopharmaceutical sector.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.

PFE

$26.49+Infinity%1D

Analyst Views on PFE

Wall Street analysts forecast PFE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PFE is 28.56 USD with a low forecast of 24.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

16 Analyst Rating

5 Buy

11 Hold

0 Sell

Moderate Buy

Current: 26.780

Low

24.00

Averages

28.56

High

35.00

Current: 26.780

Low

24.00

Averages

28.56

High

35.00

Cantor Fitzgerald

Neutral

maintain

$24 -> $27

2026-01-27

Reason

Cantor Fitzgerald

Price Target

$24 -> $27

AI Analysis

2026-01-27

maintain

Neutral

Reason

Cantor Fitzgerald raised the firm's price target on Pfizer to $27 from $24 and keeps a Neutral rating on the shares. With 2026 guidance already issued and only modest beat-and-raise potential expected, the earnings call is likely to be quiet, with focus shifting to the timing and framing of VESPER-3 obesity data, the analyst tells investors in a research note Incremental updates on the Lyme disease vaccine, mevro in prostate cancer, or sigvotatug vedotin in non-small cell lung cancer are expected to be more influential than the 4Q25 results, the firm says.

UBS

Neutral

initiated

$25

2026-01-06

Reason

UBS

Price Target

$25

2026-01-06

initiated

Neutral

Reason

UBS assumed coverage of Pfizer with a Neutral rating and $25 price target. The firm noted a backdrop of continued revenue uncertainty with $15B-$20B in revenues from key drugs losing patient exclusivity over the coming roughly three years. Though the firm is positive on the recent MTSR obesity deal, Pfizer needs to do more to offset 2028 LOE risk, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PFE

Unlock Now

About PFE

Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Pfizer Launches TrumpRx Program to Reduce Drug Costs

12 hours agoNewsfilter

Significant Drug Price Reductions: Pfizer's launch of the TrumpRx program offers substantial discounts on over 30 medications, with savings up to 85% and an average of 50%, aimed at alleviating the financial burden on American patients and enhancing their access to healthcare.
Historic Agreement Support: This initiative is part of Pfizer's landmark Most Favored Nation agreement with the Trump administration, designed to lower prescription drug prices for U.S. patients while reinforcing America's leadership in global pharmaceutical innovation.
Broad Patient Benefits: More than 100 million patients will benefit from discounted access to these medications, which treat a variety of conditions including migraines, rheumatoid arthritis, and menopause, significantly improving their quality of life and healthcare options.
Enhanced Partnerships: Pfizer's collaboration with GoodRx allows patients to use coupons at nearly any U.S. pharmacy or opt for home delivery services, further increasing flexibility and convenience in accessing medications.

Pfizer's HYMPAVZI Expands Indication for Hemophilia Treatment

35 minutes agoNewsfilter

FDA Priority Review: Pfizer announced that the FDA has accepted the supplemental Biologics License Application for HYMPAVZI and granted Priority Review, with a decision expected in Q2 2026, which will provide new treatment options for patients aged 6 and older with hemophilia, addressing the urgent market need for non-factor prophylactic therapies.
Innovative Pediatric Treatment: If approved, HYMPAVZI will become the first non-factor prophylactic treatment for children aged 6 to 11 without inhibitors, significantly improving the quality of life for these patients by reducing bleeding risks and filling a critical treatment gap.
Clinical Trial Support: The application for HYMPAVZI is supported by efficacy and safety data from the BASIS clinical trial, demonstrating its potential to reduce bleeding frequency, particularly in inhibitor patients who are unresponsive to existing factor replacement therapies, highlighting its clinical significance.
Global Market Outlook: HYMPAVZI has received regulatory approvals in over 40 countries as the first once-weekly subcutaneous prophylactic treatment, expected to drive Pfizer's market share growth in hemophilia treatment and further solidify its leadership position in the biopharmaceutical industry.